Nirvana Life Sciences focuses on developing medical products and regimens aimed at non‑addictive pain management and addiction treatment, using naturally sourced psychedelics in novel formulations. The company’s stated objective is to provide healthier outcomes for chronic pain patients and to develop therapies that could address the opioid epidemic. Nirvana describes a team of leading researchers from around the globe who will carry out its research programs. The company says its approach could free millions from addiction and save society billions annually. The only disclosed financing in the article is a $450,000 equity investment from ThreeD Capital; no operating metrics (revenue or users) are provided.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2021